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Abstract
Background: Acute respiratory illness (ARI) is the most common cause of acute presentations and hospitalisations
of young Indigenous children in Australia and New Zealand (NZ). Environmental tobacco smoke (ETS) from
household smoking is a significant and preventable contributor to childhood ARI. This paper describes the protocol
for a study which aims to test the efficacy of a family-centred tobacco control program about ETS to improve the
respiratory health of Indigenous infants in Australia and New Zealand. For the purpose of this paper ‘Indigenous’
refers to Australia’s Aboriginal and Torres Strait Islander peoples when referring to Australian Indigenous
populations. In New Zealand, the term ‘Indigenous’ refers to Māori.
Methods/Design: This study will be a parallel, randomized, controlled trial. Participants will be Indigenous women
and their infants, half of whom will be randomly allocated to an ‘intervention’ group, who will receive the tobacco
control program over three home visits in the first three months of the infant’s life and half to a control group
receiving ‘usual care’ (i.e. they will not receive the tobacco control program). Indigenous health workers will deliver
the intervention, the goal of which is to reduce or eliminate infant exposure to ETS. Data collection will occur at
baseline (shortly after birth) and when the infant is four months and one year of age. The primary outcome is a
doctor-diagnosed, documented case of respiratory illness in participating infants.
Discussion: Interventions aimed at reducing exposure of Indigenous children to ETS have the potential for
significant benefits for Indigenous communities. There is currently a dearth of evidence for the effect of tobacco
control interventions to reduce children’s exposure to ETS among Indigenous populations. This study will provide
high-quality evidence of the efficacy of a family-centred tobacco control program on ETS to reduce respiratory
illness. Outcomes of our study will be important and significant for Indigenous tobacco control in Australia and
New Zealand and prevention of respiratory illness in children.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12609000937213)
Background
Globally, acute respiratory infections (ARI) cause more
deaths and hospitalisations among Indigenous children
compared with their age-matched counterparts; the
greatest impact is among young children aged 0-4 years
[1]. Specifically, in Australia and New Zealand (NZ),
ARI is the leading cause of morbidity among Indigenous
children, resulting in more hospitalisations than any
other cause [2-4].
While there are multiple socioeconomic determinants
of ARIs among Indigenous children, environmental
tobacco smoke (ETS) exposure is arguably the most
readily amenable to modification. The adverse health
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effects of ETS are well documented, especially its asso-
ciation with respiratory illness. The association between
parental smoking and childhood respiratory disease is
strongest at younger ages [5]. In children, exposure to
ETS is causally related to the frequency and severity of
respiratory illness (especially lower respiratory illness),
as well as otitis media and chronic middle ear effusion
[6,7]. Exposure to ETS during early childhood is also
associated with an increased risk and/or worsening of
pre-existing asthma symptoms among children [8,9].
Additionally, childhood ETS exposure is associated with
sudden infant death syndrome (SIDS) [10].
In recognition of the damaging health effects of ETS,
the World Health Organization (WHO) has prioritised
the need to reduce parental smoking as a core compo-
nent of improving health and development in early
childhood [11]. This is especially important among
socioeconomically disadvantaged populations where
smoking rates among adults are higher, compared to
more advantaged groups. Indigenous Australians and
Māori New Zealanders are twice as likely to smoke as
their non-Indigenous counterparts [12,13]. High smok-
ing rates mean Indigenous children in these countries
suffer a greater burden of ETS exposure. Australian data
indicate that approximately one third of Indigenous chil-
dren aged 0-14 years live in households with a regular
smoker who smokes indoors compared with 9% of non-
Indigenous young people [14]. While there has been a
significant fall in the proportion of Maori households
where smoking is permitted indoors, age-adjusted data
from the 2006/7 NZ Health Survey found that Māori
children and children living in neighbourhoods of high
deprivation had twice the risk of exposure to ETS in
their home compared to the total population of children
surveyed [15].
Despite the recognition of the adverse child health
effects of ETS and the scale of the problem among dis-
advantaged populations in particular, exposure reduction
in homes is a relatively recent area of scientific study
[16]. A recent systematic review of family and carer
tobacco control programs for reducing children’s expo-
sure to ETS reported that of 36 studies that met inclu-
sion criteria, 11 demonstrated a statistically significant
intervention effect [17]. While the authors of this review
[17] concluded that there was insufficient evidence to
show which interventions were most effective, there
does appear to be modest empirical support for more
intensive counselling approaches for parents in this con-
text and for interventions which focus on changing par-
ticipants’ attitudes and behaviours (i.e. premised on a
theory of behaviour change), rather than just aiming to
change knowledge alone. Notably, recent qualitative
research on smoking in remote Northern Territory Indi-
genous communities found that Indigenous parents and
carers are concerned about the health effects of ETS
[18]. Moreover, their primary motivation to quit was the
health of their children, in addition to positive role
modelling. Among those who had failed to quit, some
were already taking positive steps to minimise the expo-
sure of their children to tobacco smoke. This reflects
the importance afforded to the wellbeing of the family
and in particular the fulfilment of familial responsibil-
ities towards the care and protection of children among
Indigenous Australians [19]. NZ Māori similarly have
quit for the benefit of their children, with health and
cost as other primary motivators to quit [20,21]. These
data suggest that a family based tobacco control inter-
vention, which was not predicated on adults quitting
smoking and was focused around the welfare of chil-
dren, may be particularly effective among this
population.
This study aims to test the efficacy of a culturally
appropriate, family-centred tobacco control program
about ETS to improve the respiratory health of Indigen-
ous infants in Australia and NZ.
Hypothesis
Infants (<12 months) of Indigenous mothers/caregivers
who receive an intensive family-centred tobacco control
program about ETS, compared with ‘usual care,’ will




The primary objective of this study is to determine the
efficacy of a family-centred tobacco control program
about ETS, to reduce health care presentations for
respiratory illness in Indigenous infants in the first year
of life. Secondary objectives include assessment of the
effect of such a program on a range of measures of
infant ETS exposure, including mother/caregiver’s self-
report of infant exposure to ETS and implementation of
smoking restrictions in the home and/or car, infant
urinary cotinine, household smoking status, mother/
caregiver’s smoking cessation and quit attempts. A pro-
cess evaluation of the family-centred tobacco control
program will also be undertaken.
Study Design
This study will be a parallel, randomized controlled
study with allocation concealed from the study
researchers. Participants will be randomly allocated to
one of two study arms: the ‘intervention’ group who
will receive the tobacco control program about ETS
exposure over three home visits in the first three
months of the infant’s life, or the control group who
will receive ‘usual care’ (i.e. they will not receive the
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tobacco control program). IHWs will be trained to deli-
ver the intervention program, the goal of which is to
reduce or eliminate exposure of infants to ETS. Data
collection will occur at baseline (shortly after birth), and
when the infant is four months and one year of age.
The primary outcome of interest is the rate of health
care presentations for doctor-diagnosed respiratory ill-
ness. Figure 1 outlines the flow of participants through
the study.
Study Population
This study will be conducted in Darwin City and the
Greater Darwin area in the Northern Territory, Austra-
lia; and within the Counties Manukau District Health
Board region, Manukau City, NZ. The target popula-
tions for this study are Indigenous families who reside
in these two geographical areas. The sampling unit is
Indigenous newborn infants and their mothers/primary
caregivers (aged 16 years and over).
Figure 1 Flowchart for a randomized controlled trial of a family tobacco control program about ETS to reduce respiratory illness in
Indigenous infants.
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Inclusion Criteria
Infants will be eligible for inclusion if:
• They are aged between 0-5 weeks. (We will review
our recruitment rate four months after the trial has
commenced. If we find that we are not meeting our
enrolment targets, we will consider extending our
recruitment to include infants aged 5-10 weeks. This
will allow us to approach mothers and their infants at
6-8 weeks when they present at community health
clinics for their first immunizations.)
• Their mother/caregiver is Indigenous (defined by
maternal self-identification).
• Their mother/caregiver is aged 16 years or over.
• Their mother/caregiver currently smokes or the
infant lives in a household where there is at least one
other person who smokes (defined as smoking at least
weekly).
• Their mother/caregiver plans to reside permanently
with the infant in Darwin or Greater Darwin areas of
Australia or within the Counties Manukau District
Health Board region, Manukau, NZ.
• Their mother/caregiver has given signed written
consent to participate in this research study.
• Their mother/caregiver has given signed written
consent for study staff to access the infant’s health
records.
• They are a singleton or the first born in a multiple
pregnancy delivery.
• Their mother/caregiver speaks English and/or Māori.
Exclusion Criteria
Infants will be excluded from the trial if:
• They have serious neonatal respiratory complications
(i.e. they require oxygen for >24 hours during their
postnatal hospital stay).
• They have other serious neonatal complications (e.g.
seizures, significant sepsis).
• They have major organ abnormalities (i.e. cardiac
disease, congenital lung/diaphragm abnormalities, chro-
mosomal abnormality or syndrome e.g. Down’s
syndrome).
The above exclusion criteria are because these infants
will be given intense interventions to reduce ETS expo-
sure regardless. Infants will also be excluded if:
• Their mother/caregiver has previously been recruited
in this research study.
• They live in the same household as a mother/care-
giver who has previously been recruited in this study.
Randomisation: allocation concealment and sequence
generation
Participants will be randomized by computer with strati-
fication using permuted blocks by country (Australia,
NZ) and infant age (0-5 weeks, >5-10 weeks). This will
ensure a balance in these key prognostic indicators
between the intervention and control groups. All partici-
pants (i.e. the infants) will be assigned a unique registra-
tion number allocated by a central computer following
the submission of their details on a web-based form.
Blinding
This is an assessor blinded trial, with only the study
researchers assigning the major primary and secondary
outcome measures and trial statisticians blinded to
group assignment. Research assistants, who will be
responsible for collecting the minor outcome measures
will accompany the health workers to the participants’
homes for all visits and thus cannot be blinded. The pri-
mary outcome will however be a double-blinded
measure.
Proposed intervention
Globally, Indigenous notions of health and illness are
generally defined more broadly than a Western biomedi-
cal definition that focuses more often on physical health
or the absence of disease [22]. In Australia, the National
Aboriginal Health Strategy, [[23], p.x] defines Indigen-
ous ‘health’ holistically as the physical, social, emotional,
and cultural wellbeing of the individual and the commu-
nity. In NZ, Te Whare Tapa Wha, a widely used Māori
model of health is based on the four-sided whareuni or
meeting house. It incorporates tinana (physical body),
hinengaro (psychological), whānau (family and commu-
nity), and wairua (spirit) [20]. Balance between these
dimensions is required in order to maintain stability and
good health. Poor health develops when there is a
breakdown in the harmony of these four realms within
the individual or in their relationship to the wider envir-
onment [20].
In this study, the intervention program about ETS will
be framed around an Indigenous model of health pro-
motion, which attends to the psychological, physical,
spiritual and cultural wellbeing of the individual and the
family/community, as it relates to this project. In NZ,
Te Whare Tapa Wha will be used. This model has been
applied to understanding Māori smoking cessation beha-
viour [20] and for guiding the development of culturally
appropriate smoking cessation programs and strategies
[24]. In Australia, the model will draw on similar con-
cepts. The counselling/psychological component of the
intervention program is founded on social cognitive the-
ory and motivational interviewing.
Participants will be told that they will be randomly
assigned to a group that receives ‘usual care’, or a group
that receives extra home visits by an IHW, and that a
variety of study measurements will be taken over a 12-
month period.
• Treatment group: The intervention program will (i)
provide information and education about the health
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effects of ETS exposure and use behavioural ‘coaching’
techniques to help mothers/caregivers and family mem-
bers implement strategies to reduce the infant’s ETS
exposure, as well as (ii) identify the smokers among
other household members and deliver culturally appro-
priate smoking cessation advice, counselling and treat-
ment options as requested. An eight weeks supply of
free nicotine replacement therapy (NRT) (patches or
gum) will be available to participants and other house-
hold members for whom such drug therapy is indicated
(i.e. they are motivated to quit, are nicotine dependent
and have no contraindications to taking NRT). NRT will
be provided by the IHW with appropriate counselling
and follow-up. Furthermore, for those that are interested
a fax referral to Quitline will be offered, with proactive
call back by Quitline.
The intervention program will be delivered during
three face-to-face home visits (of approximately 45-60
minutes) conducted over the first three months of the
infant’s life. Culturally appropriate resources (e.g. flip
charts, ‘No Smoking’ stickers, posters, etc) will be used
to assist in both education and behavioural ‘coaching’.
These resources will be obtained from relevant health
groups in each country who hold a repository of such
resources (e.g. QUIT Victoria, the Northern Territory
Department of Health and Families, Auckland Regional
Public Health Service). IHWs will deliver the program
after appropriate training, and will complete standar-
dised progress reports after each program session, which
will be used at a weekly team meeting with the health
workers and study personnel for discussion and ongoing
training.
• Control group: The control group will receive
‘usual’ care through their community health provider.
Usual care entails routine visits to maternal and child
health providers at several defined time points during
the first 12 months of the infant’s life. At these postnatal
visits, health providers check developmental milestones
and general wellbeing. Additionally, mothers/caregivers
routinely receive messages about smoking cessation and
ETS exposure in their homes during these visits as part
of general health promotion.
In addition to the above, the IHWs will briefly check
that both groups have received the ‘usual’ care delivered
to new mothers and their infants through routine ‘well
baby’ visits in the first 12 months of life through their
standard health provider (i.e. the study team will check
these infants are not ‘falling through the gaps’ in the
health system). This will be undertaken at baseline,
when the infant is four months and one year of age.
The focus will be on key health promotion messages
that should have been delivered at routine community
health visits (e.g. immunisations, infant nutrition/breast-
feeding and safe sleeping for baby.) Mothers/caregivers
will be given a few key messages if they have not
received this information, e.g. clear face, sleep on back
for SIDS prevention. If these visits have not been
attended or if the key messages have not been received
by the mothers/caregivers, they will be referred back to
their usual maternal and child health provider.
Outcome measures
Primary Outcome: Rate of health provider presentations
for new primary episodes of ARI in the first year of life.
All participating infants will be evaluated at baseline
and when the infant is four and 12 months old, for the
occurrence of medically attended acute respiratory ill-
nesses (MAARI). These are defined as new onset events,
including a change from the child’s baseline medical sta-
tus, referable to the upper and/or lower respiratory
tracts. To identify episodes of ARI mothers/caregivers
will be asked at baseline, and when the infant is four
and 12 months old, whether their child has had any pre-
sentation to the clinic or hospital and the names of the
clinics attended. Research assistants will collect the
source data relevant to the primary outcome measures,
so will review the individual child’s health provider and
hospital clinic records (parental consent will be obtained
prior to accessing records). Source documents will be
photocopied, de-identified, labeled with the participant
registration, and stored with the trial records. Two clini-
cians at each study centre will review the records and
confirm documented respiratory illnesses without know-
ing the group allocation of the individual children.
MAARI events will be evaluated by these clinicians to
determine whether they are medically-attended upper
respiratory infection (URI), lower respiratory infection
(LRI) and/or otitis media infection (based on the defini-
tions in Additional file 1: Table S1). Conflict will be
resolved by discussion and consensus between the two
clinicians. Intra-rater and inter-country reliability testing
will be performed on primary outcome data from 20
participants at each site. Information on antibiotic use
for the treatment of medically attended URI, LRI or oti-
tis media events will not be collected.
Major secondary outcomes:
▪ Rate of hospitalizations for ARI: same case definition
as primary outcome measure.
▪ Urinary cotinine: Urinary cotinine, a metabolite of
nicotine, is recommended as the best biomarker [25]. It
has a relatively long half-life (32-82 hours in children)
[26]. The laboratory will use gas chromatography/mass
spectrometry (GCMS) in selected-ion-monitoring mode
with a stable isotope internal standard. This method
provides a sensitive analytical method with high specifi-
city [27]. Urine samples from infants will be obtained by
placing several sterile cotton balls in a clean nappy. The
wet cotton balls will subsequently be packed into a
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sterile 20 mL syringe (without needle) and the urine
expressed into a 10 mL sterile specimen jar which will
be delivered to the contracted medical laboratory in
each country for analysis. Urinary creatinine will be
measured concurrently and results expressed as the coti-
nine/creatinine ratio (ng/mg).
Minor secondary outcomes and likely mediators of
effect:
▪ Mother/caregiver’s self-report of infant’s exposure to
ETS: Number of days in the preceding seven days in
which infant was exposed to ETS (same room in a
house with a person who smokes, in a car with a person
who smokes, or sitting outside within arm’s length of
someone who smokes).
▪ Mother/caregiver’s self-report of smoking restrictions
in the home and car.
▪ Mother/caregiver’s self-report of smoking cessation:
defined as mother/caregiver not smoking a single cigar-
ette (not even a puff), in the preceding seven days. We
will also be assessing prolonged abstinence (e.g. quit for
3 months at 4 month follow up; quit for 9 months at 12
month follow-up).
▪ Mother/caregiver’s self-report of number quit
attempts: defined as not smoking a cigarette for at least
24 hours.
▪ Process evaluation indicators: a mix of quantitative
and qualitative measures to assess how well the inter-
vention program was implemented according to proto-
col e.g. number of ‘coaching’ activities completed,
obstacles and successes in delivering program, parent
satisfaction with the program.
Sample size
A total sample size of 190 provides 90% power (5% sig-
nificance) to detect a 25% reduction of new episodes of
respiratory illness (primary outcome) in the intervention
group compared to the control group. This is based on
a conservative estimate of an average of 3 health provi-
der visits per year in the control group, compared to an
average of 2.25 visits in the intervention group (assum-
ing a Poisson distribution where the mean equals the
variance). There are few published data on the commu-
nity burden of ARIs in Northern Territory Indigenous
children or NZ Māori children. In a recent study of dis-
ease burden and clinic attendances for young Indigen-
ous children in two remote Northern Territory
communities, the median number of presentations for
upper respiratory illness in the first year of life was 7.5
(interquartile range 4-11) and for lower respiratory ill-
ness, 2.5 (interquartile range 1-5) [28]. The overall num-
ber of episodes of respiratory illness is likely to be less
in an urban setting compared to that in the remote con-
texts [29]. Thus, it is estimated that an average of 3 vis-
its per year be undertaken in the control group for the
sample size calculation above. A maximum of 10% loss
to follow-up is expected, as there are multiple contact
points throughout the study for both groups and
because the primary outcome (rate of respiratory infec-
tions) even in children who leave the study region
before 12 months of age can be measured. Thus, 210
children in each country will be recruited. Given that
there are limited data to base the likely effect size on, it
is possible that the effect size chosen may be optimistic.
By combining data from NZ and Australia the sample
size is increased to 380 participants (420 if loss to fol-
low-up is factored in), which will provide 90% power (at
5% significance level) to detect an 18% reduction in new
episodes of ARI in the intervention group compared to
the control group.
Recruitment strategies
In Australia and NZ, mothers/caregivers will be
approached for recruitment into the study through a
range of community, Indigenous-controlled health and
government hospital services. We will approach both
pregnant women and new mothers to ascertain their
interest in participating in the trial. If pregnant women
are interested in the study, we will re-approach them
after they have given birth. Eligible and interested
mothers will be asked for their consent for randomiza-
tion. Documented written consent will be obtained from
all participants prior to entering the study. A range of
project-specific advertising material will be produced
(e.g. clinic posters, brochures) and local Indigenous
media may be used to bolster recruitment.
Planned recruitment rate and risk of loss to follow up
In 2006, there were approximately 240 Indigenous
infants born to mothers who were resident in Darwin,
Australia. We anticipate that 90% or 216 Indigenous
infants/mothers will be eligible for recruitment annually
into this study. In a separate study based in Darwin to
improve ear health outcomes, 55% of Indigenous
women approached in pregnancy have consented to par-
ticipate in a randomized controlled vaccine study (pers.
comm., Dr Andrews [Menzies School of Health
Research], 10 January 2008). Using these figures, we
could confidently anticipate that approximately 108 eli-
gible Indigenous mothers will agree to participate in our
study each year, or 9 per month. This is likely to be an
underestimation, as our proposed study is less invasive
than the ongoing vaccine trial (which requires immuni-
sation and repeated blood samples).
It is anticipated that recruitment will be faster at the
Auckland site owing to a larger eligible population.
Approximately 580 babies are born each month at Mid-
dlemore Hospital, of which 21% are Māori [pers.
comm., N. Knetsch, Counties Manukau District Health
Johnston et al. BMC Public Health 2010, 10:114
http://www.biomedcentral.com/1471-2458/10/114
Page 6 of 10
Board]. Data reported in 2003 showed that about 55% of
Māori pregnant women in NZ were smoking at the time
of conception, and 15% of these women quit smoking
during their pregnancy[30] From these data we can esti-
mate that at least 57 Māori new mothers that smoke
will be available per month to approach about the trial
(mothers that are non-smokers but live in households
with other smokers are also eligible). We anticipate that
90% or 51 infants (assuming no twins) will meet the
inclusion criteria. We estimate that about 60% of
women approached will agree to participate (i.e. 31 per
month). Consequently it is expected to take about seven
months to recruit the 210 people required for the NZ
arm of the trial.
Figure 2 outlines the timeline for this study at both
sites.
Withdrawal criteria
Participants may be withdrawn from the study if one or
more of the following occurs:
• Voluntary withdrawal: A parent or primary caregiver
can voluntarily withdraw their infant from the project at
any time without having to provide a reason for doing so.
• Failure to meet eligibility criteria: An infant will be
withdrawn from the project if their mother/caregiver
has previously signed a consent form but they do not
meet all the eligibility criteria at the baseline visit (when
the infant is five weeks old +/- one week).
• Failure to be located after multiple follow-up home
visits
• Death of infant
• Significant illness requiring prolonged hospitalization
• A serious and irreconcilable protocol violation (as
determined by the Investigators)
In the event that a study participant dies, their family
contact will be asked if they require the information
recorded to be disposed of as per other participants at
the completion of the study, or whether they wish the
information to be returned to the family.
Data Management
The design and management of all databases associated
with this trial will be undertaken by the data manage-
ment and information technology groups at the Clinical
Trials Research Unit (CTRU), University of Auckland.
The databases will be constructed in Oracle. Validation
rules for each Case Report Form (CRF) will be specified
by the site study managers, in association with the
CTRU data manager. These rules will include range
checks so that inaccuracies in data collection can be
identified early. A query will be raised as soon as any
values are entered that are outside the allowed range or
if data are missing. The research assistants at each site
will amend the CRF’s as soon as a query is raised. All
information collected from participants will be treated
as strictly confidential. De-identified data will be stored
in computers under a password secure file. Paper
records will be stored under numerical code in a locked
filing cabinet within a secure office area, and will only
be accesses by approved study staff.
Data monitoring
An independent person will be appointed to monitor
the study conduct. This monitor will audit both Austra-
lia and NZ study sites and the CTRU during the trial to
ensure that the study protocol is being adhered to.
At the study sites the monitor will audit every rando-
mized participant’s records to ensure their existence,
Figure 2 Timeline for a randomized controlled trial of a family tobacco control program about ETS to reduce respiratory illness in
Indigenous infants.
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that they meet the inclusion criteria and have provided
written and signed informed consent, and that the NRT
is been distributed within the limits of the protocol. The
monitor will review the study documentation and
records held at each site to ensure that (1) documenta-
tion is up-to-date [i.e. correct version of protocol and
Manual of Procedures] and (2) record keeping meets
the requirements specified in the protocol and complies
with regulatory requirements. The monitor will visit
each site early on during the study (after ten partici-
pants have been randomized), at study close-out and
once during the course of the trial. At least 10% of
paper copies of the CRF’s will be checked for consis-
tency with the electronic records by the monitor. 100%
of electronic ARI endpoint data will be checked against
source data.
The monitor will audit the sites which hold the NRT
to check that NRT supply records are in order and that
there are sufficient supplies remaining, that the NRT are
being stored appropriately and are not being used
beyond expiry dates, and that the handling of unused
NRT complies with study procedures.
A Data Safety and Monitoring Committee will not be
established as the trial does not meet any of the criteria
stipulated by Ellenburg et al. (2002) for setting up such
a Committee [31].
Data Analyses
Statistical analyses will be performed by statisticians at
the CTRU. The statistical unit at Menzies School of
Health Research (Menzies) will play an advisory role.
Data from the trial will be entered into an Oracle data-
base at the CTRU, and then extracted into SAS version
9.2 (SAS Institute Inc. Cary NC), and R version 2.8.1 (R
Foundations for Statistical Computing) for analysis. Data
analyses will be specified a priori in a statistical analysis
plan prepared by the study statistician (and agreed upon
by all members of both the NZ and the Australian
Steering Committees). No planned interim analyses will
be undertaken of the outcome data. A baseline data
paper will be prepared after all baseline data for both
countries has been collected. The number of episodes of
ARI experienced after the intervention for each group
will be analysed on an “intention to treat” basis. Each of
the primary and secondary outcome variables will be
examined separately. There are no plans to combine
outcome variables into composite variables. Data will be
analysed for each country separately and combined. All
ETS exposure variables will be treated and examined as
outcome variables, rather than as co-variates of the pri-
mary outcome variable. Intra-rater and inter-country
agreement for grading of the primary outcome assess-
ment will be assessed using the Kappa statistic
(unweighted), with 95% confidence intervals for the
kappa statistic calculated using the method described by
Altman [32].
Baseline characteristics
All known potential confounders will be measured at
baseline, including mother/caregiver’s smoking status
(and stage of change), education level, marital status,
breastfeeding status, smoking status of partner and
other household members, crowding, and exposure of
infant to other sources of environmental smoke (e.g.
cannabis, open fires). Thus, comparisons of the inter-
vention and control groups will be performed both
unadjusted and adjusted for these known confounders.
This second adjusted analysis will control for any mal-
distribution after randomisation of the confounders
between the two groups.
Treatment effects
Analysis of the primary outcome will involve comparing
the rate of respiratory illness between the two groups.
Simple unadjusted rates, relative risks and 95% confi-
dence intervals will be obtained in the first instance,
with subsequent multiple regression analysis adjusting
for other variables. Two forms of regression analysis will
be considered for the primary outcome: poisson regres-
sion analysis and negative binomial if there is evidence
of overdispersion or underdispersion. Analysis of sec-
ondary outcomes will be conducted using standard sta-
tistical procedures applicable to categorical or
continuous data. A per-protocol analysis will also be
performed in order to check the robustness of the
results. All tests of significance will be two-tailed.
Procedures to account for missing data
For treatment effects, sensitivity analyses will be carried
out to determine the effect of missing data.
Ethics
The study will be conducted in accordance with the
Australian National Health and Medical Research Coun-
cil Guidelines on ‘Ethical Matters in Aboriginal and
Torres Strait Islander Health Research in Australia’ [33].
In Australia, the Child Health Indigenous Reference
Group at Menzies will monitor the study’s progress. It
includes representatives from consumer organizations
(e.g. local Indigenous controlled health services). This
group meets on a quarterly basis and the project team
will provide reports to this committee describing the
progress, outputs and outcomes of the project. The
Reference Group will need to authorise any publication
or dissemination of the research findings. Ethics
approval in Australia has been granted by the Human
Research Ethics Committee at Menzies (Ethics Number
09/32). Ethics approval in NZ has been granted from
the Northern Region Human Ethics Committee (Ethics
Number NTY/09/09/091). The Counties Manakau Dis-
trict Health Board Research Committee, Counties
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Manakau District Health Board Māori Research Review
Committee and the CTRU’s Māori Research Advisory
Committee have given support and input to this study
and will continue to provide guidance as it progresses.
Participants and communities will be acknowledged at
publication or presentation of the results.
Trial management
Project Managers will be responsible for the day to day
management of the trial, one in Darwin and the other
in Auckland. The Project Managers’ responsibilities
include the development of Standard Operating Proce-
dures, maintaining an up-to-date collection of essential
documents (in line with GCP requirements), monitoring
recruitment rates, attending to participant queries or
concerns and managing the fieldwork staff.
Two IHWs in each country will be responsible for
recruiting participants into the study and for delivering
the ‘intervention’ program, as well as collecting process
evaluation data. The development of Indigenous
research workforce capacity is a vital aspect of this trial.
Research assistants will collect urine samples and
administer the face-to-face questionnaire to participants.
They will also be responsible for data entry and data
cleaning, and together with the IHWs, ensure that parti-
cipant follow-up appointments are completed during the
scheduled window periods.
Two clinical investigators in Darwin and Auckland
will review participating infants’ clinical notes and code
the clinical outcome data.
Discussion
Exposure to ETS is a strong but potentially preventable
contributor to respiratory illness among young Indigen-
ous children, when household ETS exposure of children
is at its peak. Interventions aimed at encouraging smok-
ing cessation as well as reducing exposure of Indigenous
children to ETS have the potential for significant bene-
fits for Indigenous communities. This community-based,
international trial has been designed to provide high-
quality evidence of the efficacy of a theoretically and
culturally sound, intensive family-centred tobacco con-
trol program to reduce ETS exposure among Indigenous
peoples and so reduce the burden of ARI. As such, it
will make a valuable contribution to future updates of
the Cochrane review of family and carer smoking con-
trol programmes for reducing children’s exposure to
environmental tobacco smoke. The inclusion of a pro-
cess evaluation as part of the study will inform the pro-
gress and shed additional light on the outcomes of the
trial. Finally, this study seeks to incorporate Indigenous
models of health to inform the design of the interven-
tion and recruitment methods, and emphasizes Indigen-
ous capacity building at all levels.
Additional file 1: Case Definitions for Acute Respiratory Infection. A
table providing full definitions of acute respiratory infection for this study




ARI: Acute respiratory illness; ETS: Environmental tobacco smoke; sometimes
referred to as second hand smoke. Usually refers to cigarette smoke in the
environment of people who do not smoke; CTRU: Clinical Trials Research
Unit; Auckland, NZ; IHW: Indigenous health worker - either Aboriginal or
Torres Strait Islander or Māori; Menzies: Menzies School of Health Research,
Darwin, Australia; NRT: Nicotine replacement therapy, available in a range of
forms such as patch, gum lozenges, tablets and nasal spray. In this research
study, NRT will be dispensed in the form of nicotine patches and/or gum
only.
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